Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
1995 May 09;9210:4206-10.
Show Gene links
Show Anatomy links
Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W.
???displayArticle.abstract???
The estrogen receptor (ER) stimulates transcription of target genes by means of its two transcriptional activation domains, AF-1 in the N-terminal part of the receptor and AF-2 in its ligand-binding domain. AF-2 activity is dependent upon a putative amphipathic alpha-helix between residues 538 and 552 in the mouse ER. Point mutagenesis of conserved hydrophobic residues within this region reduces estrogen-dependent transcriptional activation without affecting hormone and DNA binding significantly. Here we show that these mutations dramatically alter the pharmacology of estrogen antagonists. Both tamoxifen and ICI 164,384 behave as strong agonists in HeLa cells expressing the ER mutants. In contrast to the wild-type ER, the mutant receptors maintain nuclear localization and DNA-binding activity after ICI 164,384 treatment. Structural alterations in AF-2 caused by gene mutations such as those described herein or by estrogen-independent signaling pathways may account for the insensitivity of some breast cancers to tamoxifen treatment.
Beato,
Gene regulation by steroid hormones.
1989, Pubmed
Beato,
Gene regulation by steroid hormones.
1989,
Pubmed Berry,
Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.
1990,
Pubmed Borgna,
High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite.
1980,
Pubmed Bowler,
Novel steroidal pure antiestrogens.
1989,
Pubmed Cavaillès,
Interaction of proteins with transcriptionally active estrogen receptors.
1994,
Pubmed Danielian,
Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen.
1993,
Pubmed Danielian,
Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors.
1992,
Pubmed Dauvois,
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.
1993,
Pubmed Dauvois,
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
1992,
Pubmed de Wet,
Firefly luciferase gene: structure and expression in mammalian cells.
1987,
Pubmed Evans,
The steroid and thyroid hormone receptor superfamily.
1988,
Pubmed Fuqua,
Estrogen receptor mutations in breast cancer.
1993,
Pubmed Gibson,
The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue.
1991,
Pubmed Goodrich,
Drosophila TAFII40 interacts with both a VP16 activation domain and the basal transcription factor TFIIB.
1993,
Pubmed Gorman,
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
1982,
Pubmed Green,
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A.
,
Pubmed Greene,
Immunochemical studies of estrogen receptors.
1984,
Pubmed Halachmi,
Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.
1994,
Pubmed Ham,
Regulation of gene expression by nuclear hormone receptors.
1989,
Pubmed Hoey,
Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators.
1993,
Pubmed Ing,
Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II).
1992,
Pubmed Jacq,
Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor.
1994,
Pubmed Jordan,
Endocrine pharmacology of antiestrogens as antitumor agents.
1990,
Pubmed Karnik,
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
1994,
Pubmed Klein-Hitpass,
An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells.
1986,
Pubmed
,
Xenbase Koike,
Molecular cloning and characterization of rat estrogen receptor cDNA.
1987,
Pubmed Krust,
The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors.
1986,
Pubmed Kumar,
The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer.
1988,
Pubmed Lees,
Identification of two transactivation domains in the mouse oestrogen receptor.
1989,
Pubmed Martin,
Evidence for interaction of different eukaryotic transcriptional activators with distinct cellular targets.
1990,
Pubmed Martinez,
Cooperative binding of estrogen receptor to imperfect estrogen-responsive DNA elements correlates with their synergistic hormone-dependent enhancer activity.
1989,
Pubmed
,
Xenbase Mitchell,
Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.
1989,
Pubmed Morrow,
Molecular mechanisms of resistance to tamoxifen therapy in breast cancer.
1993,
Pubmed NULL,
Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
1983,
Pubmed Pakdel,
Full-length sequence and in vitro expression of rainbow trout estrogen receptor cDNA.
1990,
Pubmed Pakdel,
Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination.
1992,
Pubmed Powles,
The case for clinical trials of tamoxifen for prevention of breast cancer.
1992,
Pubmed Ptashne,
How eukaryotic transcriptional activators work.
1988,
Pubmed Pugh,
Mechanism of transcriptional activation by Sp1: evidence for coactivators.
1990,
Pubmed Sadovsky,
Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein.
1995,
Pubmed Sporn,
Chemoprevention of cancer.
1993,
Pubmed Tasset,
Distinct classes of transcriptional activating domains function by different mechanisms.
1990,
Pubmed Tora,
The human estrogen receptor has two independent nonacidic transcriptional activation functions.
1989,
Pubmed Wahli,
Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression.
1991,
Pubmed Wakeling,
Biology and mode of action of pure antioestrogens.
1988,
Pubmed Wakeling,
A potent specific pure antiestrogen with clinical potential.
1991,
Pubmed Walker,
Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-VLDLII genes.
1984,
Pubmed
,
Xenbase Weiler,
The Xenopus laevis estrogen receptor: sequence homology with human and avian receptors and identification of multiple estrogen receptor messenger ribonucleic acids.
1987,
Pubmed
,
Xenbase White,
Structural organization and expression of the mouse estrogen receptor.
1987,
Pubmed Wolf,
The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
1994,
Pubmed Wrenn,
Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast.
1993,
Pubmed Zawel,
Advances in RNA polymerase II transcription.
1992,
Pubmed
